3.26.1 html 202 298 1 true 85 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://tonixpharma.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://tonixpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Sheet http://tonixpharma.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited) Sheet http://tonixpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) Sheet http://tonixpharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) (Parenthetical) Sheet http://tonixpharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) (Parenthetical) Statements 7 false false R8.htm 00000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://tonixpharma.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 8 false false R9.htm 00000009 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parenthetical) Sheet http://tonixpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parenthetical) Statements 9 false false R10.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 10 false false R11.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 11 false false R12.htm 999015 - Disclosure - BUSINESS Sheet http://tonixpharma.com/role/Business BUSINESS Notes 12 false false R13.htm 999016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://tonixpharma.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 13 false false R14.htm 999017 - Disclosure - INVENTORY Sheet http://tonixpharma.com/role/Inventory INVENTORY Notes 14 false false R15.htm 999018 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://tonixpharma.com/role/PropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 15 false false R16.htm 999019 - Disclosure - INTANGIBLE ASSETS Sheet http://tonixpharma.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 16 false false R17.htm 999020 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://tonixpharma.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 17 false false R18.htm 999021 - Disclosure - OTHER BALANCE SHEET INFORMATION Sheet http://tonixpharma.com/role/OtherBalanceSheetInformation OTHER BALANCE SHEET INFORMATION Notes 18 false false R19.htm 999022 - Disclosure - DEBT FINANCING Sheet http://tonixpharma.com/role/DebtFinancing DEBT FINANCING Notes 19 false false R20.htm 999023 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://tonixpharma.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 20 false false R21.htm 999024 - Disclosure - REVENUES Sheet http://tonixpharma.com/role/Revenues REVENUES Notes 21 false false R22.htm 999025 - Disclosure - ASSET PURCHASE AGREEMENT WITH UPSHER-SMITH Sheet http://tonixpharma.com/role/AssetPurchaseAgreementWithUpsher-smith ASSET PURCHASE AGREEMENT WITH UPSHER-SMITH Notes 22 false false R23.htm 999026 - Disclosure - SALE AND PURCHASE OF COMMON STOCK Sheet http://tonixpharma.com/role/SaleAndPurchaseOfCommonStock SALE AND PURCHASE OF COMMON STOCK Notes 23 false false R24.htm 999027 - Disclosure - STOCK-BASED COMPENSATION Sheet http://tonixpharma.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 24 false false R25.htm 999028 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK Sheet http://tonixpharma.com/role/WarrantsToPurchaseCommonStock WARRANTS TO PURCHASE COMMON STOCK Notes 25 false false R26.htm 999029 - Disclosure - LEASES Sheet http://tonixpharma.com/role/Leases LEASES Notes 26 false false R27.htm 999030 - Disclosure - COMMITMENTS Sheet http://tonixpharma.com/role/Commitments COMMITMENTS Notes 27 false false R28.htm 999031 - Disclosure - SUBSEQUENT EVENTS Sheet http://tonixpharma.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 28 false false R29.htm 999032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 29 false false R30.htm 999033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://tonixpharma.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://tonixpharma.com/role/SignificantAccountingPolicies 30 false false R31.htm 999034 - Disclosure - INVENTORY (Tables) Sheet http://tonixpharma.com/role/InventoryTables INVENTORY (Tables) Tables http://tonixpharma.com/role/Inventory 31 false false R32.htm 999035 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://tonixpharma.com/role/PropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://tonixpharma.com/role/PropertyAndEquipmentNet 32 false false R33.htm 999036 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://tonixpharma.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://tonixpharma.com/role/IntangibleAssets 33 false false R34.htm 999037 - Disclosure - OTHER BALANCE SHEET INFORMATION (Tables) Sheet http://tonixpharma.com/role/OtherBalanceSheetInformationTables OTHER BALANCE SHEET INFORMATION (Tables) Tables http://tonixpharma.com/role/OtherBalanceSheetInformation 34 false false R35.htm 999038 - Disclosure - REVENUES (Tables) Sheet http://tonixpharma.com/role/RevenuesTables REVENUES (Tables) Tables http://tonixpharma.com/role/Revenues 35 false false R36.htm 999039 - Disclosure - SALE AND PURCHASE OF COMMON STOCK (Tables) Sheet http://tonixpharma.com/role/SaleAndPurchaseOfCommonStockTables SALE AND PURCHASE OF COMMON STOCK (Tables) Tables http://tonixpharma.com/role/SaleAndPurchaseOfCommonStock 36 false false R37.htm 999040 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://tonixpharma.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://tonixpharma.com/role/Stock-basedCompensation 37 false false R38.htm 999041 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Tables) Sheet http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables WARRANTS TO PURCHASE COMMON STOCK (Tables) Tables http://tonixpharma.com/role/WarrantsToPurchaseCommonStock 38 false false R39.htm 999042 - Disclosure - LEASES (Tables) Sheet http://tonixpharma.com/role/LeasesTables LEASES (Tables) Tables http://tonixpharma.com/role/Leases 39 false false R40.htm 999043 - Disclosure - BUSINESS (Details Narrative) Sheet http://tonixpharma.com/role/BusinessDetailsNarrative BUSINESS (Details Narrative) Details http://tonixpharma.com/role/Business 40 false false R41.htm 999044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://tonixpharma.com/role/SignificantAccountingPoliciesTables 41 false false R42.htm 999045 - Disclosure - Information about significant segment expenses regularly provided to the CODM is as follows (in thousands): (Details) Sheet http://tonixpharma.com/role/InformationAboutSignificantSegmentExpensesRegularlyProvidedToCodmIsAsFollowsInThousandsDetails Information about significant segment expenses regularly provided to the CODM is as follows (in thousands): (Details) Details 42 false false R43.htm 999046 - Disclosure - The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statement of cash flows: (Details) Sheet http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinCondensedConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInCondensedConsolidatedStatementOfCashFlowsDetails The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statement of cash flows: (Details) Details 43 false false R44.htm 999047 - Disclosure - Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of March 31, 2026, and 2025, are as follows: (Details) Sheet http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfMarch312026And2025AreAsFollowsDetails Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of March 31, 2026, and 2025, are as follows: (Details) Details 44 false false R45.htm 999048 - Disclosure - The components of inventory consisted of the following (in thousands): (Details) Sheet http://tonixpharma.com/role/ComponentsOfInventoryConsistedOfFollowingInThousandsDetails The components of inventory consisted of the following (in thousands): (Details) Details 45 false false R46.htm 999049 - Disclosure - Property and equipment, net consisted of the following (in thousands): (Details) Sheet http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails Property and equipment, net consisted of the following (in thousands): (Details) Details 46 false false R47.htm 999050 - Disclosure - The following table provides the gross carrying amount and accumulated amortization for each major class of intangible asset: (Details) Sheet http://tonixpharma.com/role/FollowingTableProvidesGrossCarryingAmountAndAccumulatedAmortizationForEachMajorClassOfIntangibleAssetDetails The following table provides the gross carrying amount and accumulated amortization for each major class of intangible asset: (Details) Details 47 false false R48.htm 999051 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative) Sheet http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative FAIR VALUE MEASUREMENTS (Details Narrative) Details http://tonixpharma.com/role/FairValueMeasurements 48 false false R49.htm 999052 - Disclosure - Components of selected captions in the consolidated balance sheets consist of: (Details) Sheet http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails Components of selected captions in the consolidated balance sheets consist of: (Details) Details 49 false false R50.htm 999053 - Disclosure - DEBT FINANCING (Details Narrative) Sheet http://tonixpharma.com/role/DebtFinancingDetailsNarrative DEBT FINANCING (Details Narrative) Details http://tonixpharma.com/role/DebtFinancing 50 false false R51.htm 999054 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://tonixpharma.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://tonixpharma.com/role/StockholdersEquity 51 false false R52.htm 999055 - Disclosure - The Company???s net product revenues are summarized below: (Details) Sheet http://tonixpharma.com/role/CompanysNetProductRevenuesAreSummarizedBelowDetails The Company???s net product revenues are summarized below: (Details) Details 52 false false R53.htm 999056 - Disclosure - REVENUES (Details Narrative) Sheet http://tonixpharma.com/role/RevenuesDetailsNarrative REVENUES (Details Narrative) Details http://tonixpharma.com/role/RevenuesTables 53 false false R54.htm 999057 - Disclosure - ASSET PURCHASE AGREEMENT WITH UPSHER-SMITH (Details Narrative) Sheet http://tonixpharma.com/role/AssetPurchaseAgreementWithUpsher-smithDetailsNarrative ASSET PURCHASE AGREEMENT WITH UPSHER-SMITH (Details Narrative) Details http://tonixpharma.com/role/AssetPurchaseAgreementWithUpsher-smith 54 false false R55.htm 999058 - Disclosure - SALE AND PURCHASE OF COMMON STOCK (Details Narrative) Sheet http://tonixpharma.com/role/SaleAndPurchaseOfCommonStockDetailsNarrative SALE AND PURCHASE OF COMMON STOCK (Details Narrative) Details http://tonixpharma.com/role/SaleAndPurchaseOfCommonStockTables 55 false false R56.htm 999059 - Disclosure - The Company repurchased the following capital stock: (Details) Sheet http://tonixpharma.com/role/CompanyRepurchasedFollowingCapitalStockDetails The Company repurchased the following capital stock: (Details) Details 56 false false R57.htm 999060 - Disclosure - A summary of the stock option activity and related information for the Plans for the three months ended March 31, 2026, is as follows: (Details) Sheet http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForThreeMonthsEndedMarch312026IsAsFollowsDetails A summary of the stock option activity and related information for the Plans for the three months ended March 31, 2026, is as follows: (Details) Details 57 false false R58.htm 999061 - Disclosure - The assumptions used in the valuation of stock options granted during the three months ended March 31, 2026, and 2025 were as follows: (Details) Sheet http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringThreeMonthsEndedMarch312026And2025WereAsFollowsDetails The assumptions used in the valuation of stock options granted during the three months ended March 31, 2026, and 2025 were as follows: (Details) Details 58 false false R59.htm 999062 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://tonixpharma.com/role/Stock-basedCompensationTables 59 false false R60.htm 999063 - Disclosure - The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2026: (Details) Sheet http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtMarch312026Details The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2026: (Details) Details 60 false false R61.htm 999064 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Details Narrative) Sheet http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative WARRANTS TO PURCHASE COMMON STOCK (Details Narrative) Details http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables 61 false false R62.htm 999065 - Disclosure - At March 31, 2026, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details) Sheet http://tonixpharma.com/role/AtMarch312026FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails At March 31, 2026, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details) Details 62 false false R63.htm 999066 - Disclosure - Other information related to leases is as follows: (Details) Sheet http://tonixpharma.com/role/OtherInformationRelatedToLeasesIsAsFollowsDetails Other information related to leases is as follows: (Details) Details 63 false false R64.htm 999067 - Disclosure - LEASES (Details Narrative) Sheet http://tonixpharma.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://tonixpharma.com/role/LeasesTables 64 false false R65.htm 999068 - Disclosure - COMMITMENTS (Details Narrative) Sheet http://tonixpharma.com/role/CommitmentsDetailsNarrative COMMITMENTS (Details Narrative) Details http://tonixpharma.com/role/Commitments 65 false false R66.htm 999069 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://tonixpharma.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://tonixpharma.com/role/SubsequentEvents 66 false false All Reports Book All Reports tnxp-10q_033126.htm tnxp-20260331.xsd tnxp-20260331_cal.xml tnxp-20260331_def.xml tnxp-20260331_lab.xml tnxp-20260331_pre.xml http://fasb.org/srt/2026 http://fasb.org/us-gaap/2026 http://xbrl.sec.gov/dei/2026 http://xbrl.sec.gov/ecd/2026 true true